Ligand Pharmaceuticals to Showcase Insights at Investor Events
Anticipating Participation in Significant Investor Conferences
JUPITER, Fla. – Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) has exciting plans on the horizon as Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza are set to engage with investors at two major upcoming conferences.
Upcoming Conference Participation
During the Citi 20th Annual BioPharma Conference in Boston, Ligand's management will partake in a fireside chat scheduled for September 3. This conversation is anticipated to cover significant insights into the company's direction and strategies at 11:15 a.m. ET.
Following that, on September 9, the leadership team will present at the H.C. Wainwright 27th Annual Global Investment Conference in New York, where they will share updates and highlight their progress at 1:00 p.m. ET.
One-on-One Investor Engagement
Ligand's management is also gearing up to host tailored one-on-one meetings with investors and attendees during these conferences. If you're interested in arranging a personal meeting, please reach out via your Citi or H.C. Wainwright representative.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals operates as a biopharmaceutical company committed to promoting scientific advancement. The firm dedicates its resources towards supporting the clinical development of high-value medicines. By offering financing, licensing out their technologies, or a combination of both, Ligand seeks to maximize value for its shareholders.
The company's business model thrives on compiling a diversified portfolio of biotech and pharmaceutical revenues while maintaining a lean corporate cost structure. Ligand’s goal is to provide investors with opportunities to engage effectively in the burgeoning biotech landscape.
Innovative Revenue Generation
Ligand opts to fund programs in the critical mid-to-late stages of drug development. In return, they obtain economic rights, acquire royalty rights for both development-stage and commercially available biopharmaceutical products, and license their cutting-edge technology which helps partners in discovering and developing new medicines.
To boost their revenue generation, Ligand collaborates with leading pharmaceutical companies, enhancing their late-stage development, regulatory management, and commercialization endeavors. This strategic partnership approach maximizes the overall effectiveness of their ventures.
Advanced Platform Technologies
Ligand excels with two technology IP platform technologies that generate royalties with minimal infrastructure. Their Captisol® platform technology utilizes a chemically modified cyclodextrin to enhance drug solubility and stability effectively.
Additionally, the NITRICIL™ technology enables flexible dosing options, allowing for an adjustable drug release profile that is beneficial across multiple indications. The effectiveness and adaptability of these platforms position Ligand alongside prominent pharmaceutical partners such as Amgen, Merck, Pfizer, Jazz, Gilead Sciences, and Baxter International.
Continued Commitment to Investor Relations
For further insights, visit Ligand's investor relations website and follow their updates on various platforms. The company frequently discloses key material non-public information through these channels, ensuring transparency while navigating regulatory obligations.
Stay Connected
Investors are encouraged to monitor Ligand’s website, social media handles, press releases, SEC filings, and public conferences. Keep an eye out for real-time updates that could influence your investment decisions.
Contact Information
Investors:
Melanie Herman
investors@ligand.com
(858) 550-7761
Media:
Kellie Walsh
media@ligand.com
(914) 315-6072
Frequently Asked Questions
What investor conferences is Ligand Pharmaceuticals attending?
Ligand is set to participate in the Citi 20th Annual BioPharma Conference and the H.C. Wainwright 27th Annual Global Investment Conference.
Who from Ligand Pharmaceuticals will be attending the conferences?
CEO Todd Davis and CFO Tavo Espinoza will represent the company during these events.
Can investors schedule one-on-one meetings during the conferences?
Yes, investors can arrange one-on-one meetings by contacting their Citi or H.C. Wainwright representative.
What is the primary focus of Ligand Pharmaceuticals?
Ligand is focused on supporting the clinical development of high-value medicines through innovative business models and technologies.
How can I learn more about Ligand Pharmaceuticals?
For more information, visit their website and follow them on social media platforms for the latest updates.
About The Author
Contact Riley Hayes privately here. Or send an email with ATTN: Riley Hayes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.